Markets & Regulations

© Getty Images

J&J’s Akeega FDA approval to heat up PARP battle

By Isabel Cameron

The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic castration-resistant prostate cancer (mCRPC).

© Getty Images

ImmunoGen to develop next-generation ADCs with ImmunoBiochem

By Isabel Cameron

ImmunoGen, a biotech company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer, has announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem, a biopharma firm...

© Getty Images

MaaT Pharma joins Microbiome Therapeutics Innovation Group

By Isabel Cameron

MaaT Pharma, a clinical-stage biotech company focused on the development of Microbiome Ecosystem Therapies (MET) dedicated to improving survival outcomes for patients with cancer, is now a member of Microbiome Therapeutics Innovation Group (MTIG).

© Getty Images

Donaldson acquires Univercells Technologies for €136 million

By Isabel Cameron

Donaldson, a provider of filtration products and solutions, has acquired Univercells Technologies, a producer of biomanufacturing solutions for cell and gene therapy research, development, and commercial manufacturing, to broaden its life sciences reach....

© Getty Images

Oliva Therapeutics partners with Rio Biopharmaceuticals

By Isabel Cameron

Oliva Therapeutics, a healthcare company focused on product commercialization, sales, marketing, distribution, and promotion, has announced its new long-term partnership with Rio Biopharmaceuticals, for the exclusive North American supply and distribution...